Codexis Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis or view top-rated stocks.

4 brokerages have issued 12-month price objectives for Codexis' stock. Their CDXS stock forecasts range from $30.00 to $39.00. On average, they anticipate Codexis' stock price to reach $35.25 in the next year. This suggests a possible upside of 193.8% from the stock's current price.
View analysts' price targets for Codexis or view top-rated stocks among Wall Street analysts.

Codexis' stock was trading at $31.27 at the beginning of the year. Since then, CDXS shares have decreased by 61.6% and is now trading at $12.00.
View the best growth stocks for 2022 here.

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. The biotechnology company had revenue of $35.34 million for the quarter, compared to analysts' expectations of $28.58 million. Codexis had a negative trailing twelve-month return on equity of 12.56% and a negative net margin of 16.85%. The business's revenue for the quarter was up 96.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.14) earnings per share.
View Codexis' earnings history.

Codexis issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $152.00 million-$158.00 million, compared to the consensus revenue estimate of $155.49 million.

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of CDXS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $12.00.

Codexis (NASDAQ:CDXS) has a market capitalization of $783.60 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

Codexis employs 261 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for Codexis is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.